NCT01536054 - Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2012

Primary Completion Date

April 21, 2015

Study Completion Date

April 21, 2015

Conditions

Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IIA Fallopian Tube CancerStage IIA Ovarian Epithelial CancerStage IIA Primary Peritoneal Cavity CancerStage IIB Fallopian Tube CancerStage IIB Ovarian Epithelial CancerStage IIB Primary Peritoneal Cavity CancerStage IIC Fallopian Tube CancerStage IIC Ovarian Epithelial CancerStage IIC Primary Peritoneal Cavity CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian Epithelial CancerStage IIIA Primary Peritoneal Cavity CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian Epithelial CancerStage IIIB Primary Peritoneal Cavity CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian Epithelial CancerStage IIIC Primary Peritoneal Cavity CancerStage IV Fallopian Tube CancerStage IV Ovarian Epithelial CancerStage IV Primary Peritoneal Cavity Cancer

Interventions

BIOLOGICAL

ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine

Given SC

DRUG

sirolimus

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

BIOLOGICAL

sargramostim

Given SC

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER